Content Menu
● Is Benzocaine Safe in Pregnancy?
>> Pregnancy Risk Category and Evidence
>> Regulatory and Professional Guidance
● When Might Benzocaine Be Used in Pregnancy?
● Potential Risks of Benzocaine in Pregnancy
>> Systemic Absorption and Methemoglobinemia
● Safer Alternatives to Benzocaine During Pregnancy
● Practical Tips for Pregnant Women Considering Benzocaine
● How a Professional OEM Manufacturer Can Help
● FAQ
>> 1. Is it ever safe to use benzocaine while pregnant?
>> 2. Can benzocaine cause birth defects?
>> 3. Is benzocaine or lidocaine better during pregnancy?
>> 4. What symptoms should a pregnant woman watch for after using benzocaine?
>> 5. How can an OEM partner help design safer benzocaine products for pregnant users?
Benzocaine is widely used as a topical local anesthetic in over‑the‑counter (OTC) and prescription products for relieving minor pain, itching, and discomfort. During pregnancy, however, safety becomes a crucial concern, and both healthcare professionals and manufacturers must consider how, when, and whether benzocaine should be used in this sensitive population. This article reviews what benzocaine is, how it works, what is known about its safety in pregnancy, its potential risks, safer alternatives, and practical recommendations. It also explains how a professional OEM manufacturer can help brands develop products that better align with modern safety expectations for pregnant users.
Benzocaine is a short‑acting local anesthetic that works by blocking sodium channels in nerve endings, thereby preventing the initiation and transmission of nerve impulses that carry pain signals. When applied topically to the skin or mucous membranes, it produces temporary numbness in the treated area.
Common benzocaine‑containing formulations include:
- Oral gels and lozenges for mouth or throat pain
- Topical creams, sprays, and ointments for skin irritation or minor injuries
- Hemorrhoidal and perianal relief products
- Dental topical gels and liquids used before injections or minor procedures
In most OTC and professional products, benzocaine concentrations range between about 5% and 20%. The amount of benzocaine that enters the bloodstream (systemic absorption) depends on several factors, including concentration, the size of the application area, the condition of the skin or mucosa (intact or damaged), frequency of use, and duration of contact.
Because pregnancy involves physiological changes (such as increased blood volume, altered enzyme activity, and changes in skin and mucosal blood flow), the way the body absorbs, distributes, and eliminates anesthetics can differ compared with non‑pregnant adults. These changes are part of the reason why careful risk–benefit assessment is important when using benzocaine or any local anesthetic in pregnant women.
Under the older U.S. FDA pregnancy category system, benzocaine was generally grouped with local anesthetics that have limited human data and some concerning findings in animal studies, roughly corresponding to pregnancy Category C. This means animal studies reported adverse effects on the fetus at certain dose levels, but adequate, well‑controlled studies in pregnant women were lacking. Today, many labels no longer use the letter categories and instead provide narrative descriptions of potential risk, but the interpretation is essentially the same: use benzocaine in pregnancy only if the potential benefit justifies the possible risk.
Available human data are limited but somewhat reassuring when benzocaine is used in small doses as intended. Classic observational work on local anesthetics in pregnancy has not demonstrated a clear increase in congenital anomalies when exposure occurred in early pregnancy. Furthermore, teratology information services (such as MotherToBaby) note that topical benzocaine used as directed on the skin or mucosa leads to relatively low systemic absorption, implying that fetal exposure should also be low and the likelihood of birth defects from such exposure appears low.
However, the absence of strong evidence of harm is not the same as proof of safety. Because robust, controlled human studies are lacking and some animal data are concerning at high doses, professional guidelines generally favor using better‑studied alternatives (particularly lidocaine) whenever possible, and recommend that benzocaine be reserved for specific situations in which its benefits clearly outweigh potential risks.
Regulators and professional bodies have focused heavily on benzocaine safety, particularly in infants and young children, but many of the underlying safety issues are relevant to pregnant women as well. Authorities have highlighted the risk of methemoglobinemia associated with benzocaine‑containing oral products. Methemoglobinemia is a serious condition in which hemoglobin is oxidized to a form that cannot carry oxygen effectively, leading to functional anemia and reduced oxygen delivery to tissues.
Although most published cases of benzocaine‑induced methemoglobinemia involve infants, young children, or adults exposed to high or repeated doses, the mechanism is applicable at any age. In pregnancy, the stakes are higher because hypoxia can harm both mother and fetus. As a result, many obstetric and dental references recommend lidocaine (with or without epinephrine) as the primary local anesthetic agent in pregnant patients, with benzocaine used sparingly and only when clearly necessary.
In dental care, for example, standard local anesthesia using lidocaine is generally considered safe throughout pregnancy when used within recommended dosage limits. Topical benzocaine is widely present in dental practice, but many experts prefer lidocaine‑based topical agents or carefully restrict the use of benzocaine, especially when treating pregnant women or patients with additional risk factors for methemoglobinemia.
In clinical practice, benzocaine is occasionally used in pregnant women for short‑term, localized pain relief when other options are ineffective, unavailable, or not practical. Typical scenarios may include:
- Local oral discomfort: mild mouth ulcers, gingival irritation, or minor trauma where a topical anesthetic is needed for a short period.
- Dental procedures: as a topical anesthetic before injection when benzocaine is the standard product stocked in the clinic, or when patients have specific preferences or sensitivities.
- Local perianal or hemorrhoidal pain: in combination products designed to relieve burning, itching, or soreness in the anal or genital region.
Even in these situations, most experts recommend that clinicians:
- Prefer lidocaine‑containing products, especially those with established pregnancy safety data, when they are clinically suitable and available.
- Use the lowest possible benzocaine concentration that provides adequate relief.
- Apply to the smallest area needed, for the shortest duration needed.
- Avoid using benzocaine on large, inflamed, or broken areas of skin or mucosa, which can increase systemic absorption.
Because the goal in pregnancy is to minimize fetal exposure while maintaining adequate maternal comfort and function, benzocaine tends to be viewed as a secondary option rather than the default first‑line agent.
The most serious documented risk of benzocaine is methemoglobinemia. When significant amounts of benzocaine are absorbed into the blood, it can oxidize hemoglobin to methemoglobin, which is unable to bind and carry oxygen efficiently. If methemoglobin levels become high, the patient can experience tissue hypoxia and, in severe cases, life‑threatening complications.
Common warning signs and symptoms of methemoglobinemia include:
- Pale, gray, or blue‑colored skin, lips, or nail beds
- Shortness of breath or rapid breathing
- Fatigue, dizziness, or lightheadedness
- Rapid heart rate
- Headache or confusion
Methemoglobinemia has been reported after topical benzocaine use, especially when applied frequently, used in excessive amounts, sprayed into the mouth or throat repeatedly, or used in vulnerable individuals (such as infants or people with certain enzyme deficiencies). While these reports do not focus specifically on pregnant women, the underlying risk is relevant, and pregnant patients may be more vulnerable to the consequences of hypoxia because of increased oxygen demands and physiologic changes in the respiratory and cardiovascular systems.
From the fetal perspective, there are two main issues:
1. Direct drug effects on the fetus
Existing human data do not clearly show that benzocaine causes birth defects, miscarriages, or growth restriction when used in normal topical doses during pregnancy. Limited studies and case series have not demonstrated a strong teratogenic signal for local anesthetics as a group at therapeutic doses. Nevertheless, because robust, large‑scale studies are absent and animal studies have reported adverse fetal effects at higher exposure levels, benzocaine is generally categorized more cautiously than lidocaine.
2. Indirect effects through maternal hypoxia
Even if benzocaine itself does not directly damage fetal organs, maternal methemoglobinemia and resulting hypoxia can reduce oxygen supply to the fetus. If severe and uncorrected, maternal hypoxia can be harmful to fetal development and immediate fetal well‑being. This indirect pathway is one of the most important concerns about high or repeated exposure to benzocaine in pregnancy.
Given these potential risks and the availability of safer alternatives, many clinicians and guideline authors advise restricting benzocaine use in pregnancy and turning first to agents with more favorable and better‑documented safety profiles.
For most indications in pregnant women, lidocaine is the preferred local anesthetic. It has been extensively used in obstetrics and dentistry for decades, with a strong track record of safety when used appropriately.
Key points about lidocaine and other alternatives:
1. Lidocaine (with or without epinephrine)
Lidocaine is generally considered safe for use during pregnancy at standard therapeutic doses. In dental practice, 2% lidocaine with low‑dose epinephrine is routinely used for restorative work, extractions, and other procedures throughout pregnancy. Large clinical experience and studies have not demonstrated an increase in congenital anomalies or adverse pregnancy outcomes when dosage limits are respected.
2. Topical lidocaine‑based products
Topical creams, gels, or patches containing lidocaine alone or in combination with other agents (such as prilocaine) are widely used to numb the skin before minor procedures. While package inserts may still advise caution, these formulations are typically regarded as acceptable in pregnancy when used according to instructions, on limited surface areas, and for limited durations.
3. Non‑drug methods
For mild discomforts, non‑pharmacologic measures—such as saline mouth rinses for oral irritation, cool compresses for minor skin injuries, sitz baths for hemorrhoidal discomfort, and good hygiene—can significantly reduce symptoms without exposing the mother or fetus to local anesthetics. These approaches should generally be tried first for mild, self‑limited conditions.
By prioritizing lidocaine‑based formulations and non‑drug measures, healthcare professionals can usually manage routine pregnancy‑related or incidental pain without needing to rely heavily on benzocaine. This approach aligns clinical practice with current safety data and regulatory expectations.
Pregnant women often self‑treat minor symptoms with OTC products. When benzocaine‑containing items are available on pharmacy shelves, clear guidance is essential to avoid inappropriate use. Practical recommendations include:
1. Consult a healthcare professional before use
Pregnant women should discuss any persistent pain or discomfort with their obstetrician, midwife, dentist, or pharmacist before starting benzocaine. A professional can confirm that the symptom is benign, suggest non‑drug measures, and recommend safer alternatives such as lidocaine if needed.
2. Use the lowest effective dose on the smallest area
If benzocaine use is deemed appropriate, the product should be applied sparingly to a limited area, no more often than directed on the label. Over‑application does not dramatically increase pain relief but does increase the risk of systemic absorption and side effects.
3. Avoid long‑term or frequent use
Benzocaine should be used for the shortest duration necessary to control symptoms. Prolonged or repeated use, especially on mucosal surfaces like the mouth or genital area, can significantly increase systemic exposure.
4. Do not use on large or damaged areas
Applying benzocaine to large body surfaces, open wounds, or severely inflamed tissue can sharply increase absorption and the risk of adverse effects. Pregnant women should avoid these practices unless they are specifically instructed otherwise by a healthcare provider.
5. Be alert for symptoms of methemoglobinemia or allergic reactions
If a pregnant woman notices gray or blue discoloration of the skin or lips, sudden or unexplained shortness of breath, rapid heartbeat, unusual fatigue, dizziness, or confusion after using benzocaine, she should stop using the product immediately and seek urgent medical attention. Similarly, signs of an allergic reaction—such as rash, itching, swelling, or difficulty breathing—require immediate care.
6. Consider whether non‑drug options are adequate
Many common discomforts in pregnancy are short‑lived and respond well to simple measures such as rest, hydration, cold or warm compresses, good hygiene, and topical non‑anesthetic agents (for example, barrier creams for minor skin irritation). If symptoms are improving with these methods, adding benzocaine may not be necessary.
These precautions help ensure that when benzocaine is used during pregnancy, it is used in a way that minimizes risk to both mother and baby.
For international brands, wholesalers, and manufacturers serving markets that include pregnant or reproductive‑age women, product design and ingredient selection are strategic decisions as much as scientific ones. Working with a specialized OEM manufacturer provides a critical advantage in balancing efficacy, safety, and commercial appeal.
As a Chinese factory engaged in biotechnology, pharmaceuticals, and medical devices, we provide comprehensive OEM services for benzocaine‑based and alternative local‑anesthetic products. Our support to global partners includes:
1. Formulation design optimized for pregnancy‑sensitive markets
We can help you design formulations that prioritize active ingredients with stronger pregnancy safety profiles, such as lidocaine‑based topical products, or carefully balanced combinations when benzocaine is desired. Through controlled concentration, excipient selection, and dosage form engineering, we aim to minimize systemic absorption while maintaining reliable local pain relief.
2. Flexible dosage forms
We offer OEM production for a wide range of dosage forms, including oral gels, mouth sprays, lozenges, skin creams, ointments, foams, and perianal or hemorrhoidal preparations. This flexibility allows you to tailor products to specific patient needs and regulatory environments.
3. Quality management and compliance
Our manufacturing adheres to rigorous quality systems, with attention to raw material selection, process control, and finished‑product testing. We can provide comprehensive technical documentation to support your local registration, quality audits, and pharmacovigilance obligations.
4. Regulatory and technical support
We stay informed about evolving global expectations for local anesthetics, including pregnancy‑related labeling and safety considerations. Our technical team can help you prepare dossiers, respond to regulatory queries, and align product positioning with current clinical guidance.
5. Co‑development and long‑term partnership
Rather than offering only standard formulas, we can collaborate with you from early concept through scale‑up and commercialization. This includes pilot batches, stability studies, packaging development, and iterative optimization based on market feedback.
By integrating scientific knowledge of anesthetics, manufacturing expertise, and regulatory awareness, we help our partners bring to market products that better meet the needs of pregnant users and their healthcare providers. Whether your portfolio focuses on oral care, dermatology, hemorrhoidal relief, or multi‑purpose topical anesthetics, we can support you in building formulations that are both effective and responsibly designed.
Benzocaine is not absolutely contraindicated in pregnancy, and limited, localized, short‑term topical use is generally considered to carry low risk when used as directed. However, it is not the preferred anesthetic for pregnant women because high‑quality human data are limited and benzocaine carries a rare but serious risk of methemoglobinemia, which can compromise oxygen delivery to both mother and fetus. Most modern obstetric and dental references therefore favor lidocaine‑based local anesthetics as the first‑line choice during pregnancy, relying on their extensive safety record and well‑established dosing guidelines.
For healthcare professionals and pregnant patients, the safest approach is to reserve benzocaine for situations where benefits clearly outweigh potential risks, to use the lowest effective dose on the smallest area for the shortest time, and to remain vigilant for signs of adverse effects. For brands and manufacturers, the same principles translate into formulation choices, labeling, and educational materials that emphasize safer alternatives and responsible use.
As an experienced OEM manufacturer in biotechnology, pharmaceuticals, and medical devices, we are ready to help you design, optimize, and produce benzocaine‑containing or alternative anesthetic products that align with these safety expectations. If you are planning to develop or upgrade products aimed at pregnant or reproductive‑age consumers, we invite you to contact us through supplybenzocaine.co.uk to discuss customized formulations, sample development, and long‑term cooperation. Together, we can create high‑quality, scientifically grounded products that serve your customers' needs while respecting the unique safety considerations of pregnancy. Contact us to get more information!
For most healthy pregnant women, occasional, small‑area topical use of benzocaine (for example, a short course of oral gel for minor mouth pain) is generally considered low risk when used strictly as directed. Because pregnancy is a sensitive period, however, benzocaine should not be used routinely or in large amounts without medical advice. It is always best to consult a healthcare professional before using any benzocaine‑containing product during pregnancy.
Current human data do not show a clear link between benzocaine exposure at usual topical doses and birth defects. Limited studies on local anesthetics as a group have not demonstrated a significant increase in congenital anomalies when used appropriately during pregnancy. Nevertheless, because definitive, large‑scale studies are lacking and some animal data show adverse effects at high doses, benzocaine is treated with caution. The general recommendation is to avoid unnecessary or prolonged use in pregnancy and to choose better‑studied alternatives when possible.
Lidocaine is usually preferred over benzocaine in pregnancy because it has more extensive human safety data and has long been used safely in obstetrics and dentistry at standard doses. Topical or injectable lidocaine is widely accepted as the first‑line local anesthetic for pregnant patients. Benzocaine, by contrast, has less robust human data and carries a known, though rare, risk of methemoglobinemia. For these reasons, benzocaine is typically considered a second‑line option, used only when clearly indicated and under professional supervision.
After using a benzocaine product, a pregnant woman should stop using it immediately and seek urgent medical care if she notices gray, pale, or bluish skin, lips, or nail beds, sudden shortness of breath, rapid heart rate, unexplained fatigue, dizziness, headache, or confusion. These symptoms may indicate methemoglobinemia or another serious reaction that requires prompt treatment. She should also seek medical attention if she experiences signs of allergy, such as rash, itching, swelling, or difficulty breathing.
A skilled OEM partner can help you choose optimal active ingredients, concentrations, and dosage forms to reduce systemic exposure while maintaining adequate pain relief. This may involve prioritizing lidocaine‑based formulations or using benzocaine only in carefully controlled, lower‑risk settings. The OEM partner can also support you with high‑quality manufacturing, stability and compatibility studies, regulatory documentation, and technical guidance, ensuring that your branded products align with current clinical recommendations and safety expectations for pregnant populations.
1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5418954/
2. https://www.aafp.org/news/health-of-the-public/20180530fdabenzocaine.html
3. https://www.dentalcare.com/en-us/ce-courses/ce325/local-anesthesia-and-pregnancy
4. https://dimensionsofdentalhygiene.com/article/managing-pain-with-topical-anesthetics/
5. https://www.fda.gov/drugs/drug-safety-and-availability/risk-serious-and-potentially-fatal-blood-disorder-prompts-fda-action-oral
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10315135/
7. https://www.webmd.com/baby/facial-while-pregnant-what-to-know
8. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-reports-rare-serious-and-potentially-fatal
9. https://www.sciencedirect.com/science/article/abs/pii/S1532338223000040
10. https://mothertobaby.org/fact-sheets/benzocaine/pdf/
Hot tags: Benzocaine Safety During Pregnancy, Is Benzocaine Safe While Pregnant, Benzocaine Pregnancy Category FDA, Can I Use Orajel While Pregnant, Topical Benzocaine Pregnancy Safety, Benzocaine Throat Spray Pregnancy, Benzocaine Side Effects During Pregnancy, Safe Mouth Pain Relief Pregnancy, Is Benzocaine Gel Safe For Pregnancy, Benzocaine Risk Pregnancy Methemoglobinemia